# US 11,299,764 B2 · Single spin process for blood plasma separation and plasma composition including preservative > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,299,764 B2 - Document ID: US11299764B2 - Status: Granted - Kind: B2 - Application number: 16/233,880 - Filed: 2018-12-27 - Published: 2019-05-02 - Granted: 2022-04-12 - Earliest claimed: 2015-11-20 - Assignees: Streck, Inc. - Applicants: Streck, Inc. - Inventors: Bradford A. Hunsley; Jianbing Qin - Web page: https://patentgrep.com/patent/US11299764B2 ## CPC - C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) - C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor} - C12Q 1/686: Polymerase chain reaction [PCR] - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract A screening method for the identification of a characteristic of a target nucleic acid in a whole blood sample, including positioning a composition comprising whole blood and at least one preservative agent within a centrifuge, centrifugating the composition to isolate a plasma that includes at least one target nucleic acid for further analysis and analyzing the at least one target nucleic acid to identify a characteristic about the at least one target nucleic acid, and a composition including the plasma, the preservative agent, and any other ingredient, which is produced by the method. ## Claims ### Claim 1 A method for identifying a characteristic of a target nucleic acid in a whole blood sample, comprising the steps of: a. positioning a composition comprising whole blood and a protective agent comprising at least one preservative agent within a centrifuge, wherein the preservative agent is selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5dimethylhydantoin, dimethylol urea, 2-bromo-2.-nitropropane-1,3-diol, oxazolidines, sodium hydroxymethyl glycinate, 5-hydroxymethoxymethyl-1-1aza-3,7-dioxabicyclo [3.3.0]octane, 5-hydroxymethyl- 1-1 aza-3,7dioxabicyclo[3.3.0]octane, 5-hydroxypoly[methyleneoxy]methyl-1-1 aza-3, 7dioxabicyclo[3.3.0]octane, quaternary adamantine and any combination thereof; b. centrifugating the composition at a speed of at least about 1000 g and below about 4500 g for at least about 5 minutes and less than about 20 minutes to isolate a plasma that includes the target nucleic acid for further analysis; c. isolating and testing the target nucleic acid obtained from step b to identify the characteristic of the target nucleic acid, wherein the method is free of any second centrifugating step, and wherein the target nucleic acid is cell-free plasma nucleic acid. ### Claim 2 (depends on 1) The method of claim 1, wherein the concentration of the preservative agent prior to the centrifugating step is between about 1% and about 30%. ### Claim 3 (depends on 1) The method of claim 1, wherein the concentration of the preservative agent is less than about 2% of the blood sample. ### Claim 4 (depends on 1) The method of claim 1, wherein the composition further includes one or more other nonaqueous ingredients selected from the group consisting of glycine, lysine, ethylene diamine, arginine, urea, adenine, guanine, cytosine, thymine, spermidine, ethylenediaminetetraacetic acid (EDTA), aurintricarboxylic acid (ATA), glyceraldehyde, and sodium fluoride. ### Claim 5 (depends on 1) The method of claim 1, wherein the centrifugating step consists of a single step of centrifugating the composition at a speed below about 2500 g. ### Claim 6 (depends on 1) The method of claim 1, wherein the centrifugating step consists of a single step of centrifugating the composition at a speed of at least about 1500 g. ### Claim 7 (depends on 1) The method of claim 1, wherein the total time of the centrifugation is below about 18 minutes. ### Claim 8 (depends on 1) The method of claim 1, wherein one or more of the centrifugating, isolating, or testing steps occurs within 14 days after the blood sample is drawn. ### Claim 9 (depends on 1) The method of claim 1, wherein the characteristic is a chromosomal abnormality. ### Claim 10 (depends on 1) The method of claim 1, wherein the centrifugating is performed at room temperature. ### Claim 11 (depends on 1) The method of claim 1, wherein the testing step includes performing droplet digital PCR. ### Claim 12 (depends on 1) The method of claim 1, wherein the total time of centrifugation is below about 12 minutes. ### Claim 13 (depends on 1) The method of claim 1, wherein one or more of the centrifugating, isolating, or testing steps occurs without freezing the blood sample. ### Claim 14 (depends on 1) The method of claim 1 wherein the testing step includes performing polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), quantitative real time polymerase chain reaction (Q-PCR), gel electrophoresis, capillary electrophoresis, mass spectrometry, fluorescence detection, ultraviolet spectrometry, DNA hybridization, allele specific polymerase chain reaction, polymerase cycling assembly (PCA), asymmetric polymerase chain reaction, linear after the exponential polymerase chain reaction (LATE-PCR), helicase-dependent amplification (HDA), hot-start polymerase chain reaction, intersequence-specific polymerase chain reaction (ISSR), inverse polymerase chain reaction, ligation mediated polymerase chain reaction, methylation specific polymerase chain reaction (MSP), multiplex polymerase chain reaction, nested polymerase chain reaction, solid phase polymerase chain reaction, or a combination thereof. ### Claim 15 (depends on 1) The method of claim 1, wherein the protective agent comprises about 0.05 to about 0.4 grams of the at least one preservative agent per 0.2 ml of the protective agent. ### Claim 16 (depends on 4) The method of claim 4, wherein the EDTA is K3EDTA. ### Claim 17 (depends on 4) The method of claim 4, wherein the EDTA is present in an amount of about 20 g/l to about150 g/l of the protective agent. ### Claim 18 (depends on 17) The method of claim 17, wherein the EDTA is present in an amount of about 50 g/l to about 100 g/l of the protective agent. ### Claim 19 (depends on 4) The method of claim 4, wherein the glycine is present in an amount of about 10 g/l to about 150 g/l of the protective agent. ### Claim 20 (depends on 19) The method of claim 19, wherein the glycine is present in an amount of about 35 g/l to about 100 g/l of the protective agent. ### Claim 21 (depends on 1) The method of claim 1, wherein the imidazolidinyl urea is present in an amount of about 300 g/l to about 700 g/l of the protective agent. ### Claim 22 (depends on 1) The method of claim 1, wherein the diazolidinyl urea is present in an amount of about 50 g/l to about 400 g/l of the protective agent. ### Claim 23 (depends on 1) The method of claim 1, wherein the composition comprises about 0.05 to about 1.0 ml of the protective agent. ### Claim 24 (depends on 1) The method of claim 1, wherein the composition comprises about 0.1 to about 0.3 ml of the protective agent. ### Claim 25 (depends on 1) The method of claim 1, wherein the composition comprises about 0.2 ml of the protective agent. ### Claim 26 (depends on 1) The method of claim 1, wherein the composition comprises about 10 ml of the whole blood. ### Claim 27 A method for identifying a characteristic of a target nucleic acid in a whole blood sample comprising the steps of: a. positioning a composition comprising whole blood and a protective agent comprising at least one preservative agent within a centrifuge, wherein the preservative agent is selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5dimethylhydantoin, dimethylol urea, 2-bromo-2.-nitropropane-1,3-diol, oxazolidines, sodium hydroxymethyl glycinate, 5-hydroxymethoxymethyl-1-1aza-3,7- dioxabicyclo [3.3.0]octane, 5-hydroxymethyl-1-1aza-3,7dioxabicyclo[3.3.0]octane, 5- hydroxypoly[methyleneoxy]methyl-1-1aza-3, 7dioxabicyclo[3.3.0]octane, quaternary adamantine and any combination thereof; b. centrifugating the composition at a speed of about 1600 g for about 15 minutes to isolate a plasma that includes the target nucleic acid for further analysis; and c. isolating and testing the target nucleic acid obtained from step b to identify the characteristic of the target nucleic acid, wherein the method is free of any second centrifugating step, and wherein the target nucleic acid is cell-free plasma nucleic acid. ### Claim 28 (depends on 27) The method of claim 27, wherein the characteristic is a chromosomal abnormality. ### Claim 29 (depends on 27) The method of claim 27, wherein the concentration of the preservative agent prior to the centrifugating step is between about 1% and about 30%. ### Claim 30 (depends on 27) The method of claim 27, wherein the composition further includes one or more other nonaqueous ingredients selected from the group consisting of glycine, lysine, ethylene diamine, arginine, urea, adenine, guanine, cytosine, thymine, spermidine, ethylenediaminetetraacetic acid (EDTA), aurintricarboxylic acid (ATA), glyceraldehyde, and sodium fluoride. ### Claim 31 (depends on 27) The method of claim 27, wherein the centrifugating is performed at room temperature. ### Claim 32 (depends on 27) The method of claim 27, wherein the testing step includes performing droplet digital PCR. ### Claim 33 (depends on 27) The method of claim 27, wherein the total time of centrifugation is below about 12 minutes. ### Claim 34 (depends on 27) The method of claim 27, wherein the concentration of the preservative agent is less than about 2% of the blood sample. ### Claim 35 (depends on 27) The method of claim 27, wherein one or more of the centrifugating, isolating, or testing steps occurs within 14 days after the blood sample is drawn. ### Claim 36 (depends on 27) The method of claim 27 wherein the testing step includes performing polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), quantitative real time polymerase chain reaction (Q-PCR), gel electrophoresis, capillary electrophoresis, mass spectrometry, fluorescence detection, ultraviolet spectrometry, DNA hybridization, allele specific polymerase chain reaction, polymerase cycling assembly (PCA), asymmetric polymerase chain reaction, linear after the exponential polymerase chain reaction (LATE-PCR), helicase-dependent amplification (HDA), hot-start polymerase chain reaction, intersequence-specific polymerase chain reaction (ISSR), inverse polymerase chain reaction, ligation mediated polymerase chain reaction, methylation specific polymerase chain reaction (MSP), multiplex polymerase chain reaction, nested polymerase chain reaction, solid phase polymerase chain reaction, or a combination thereof. ### Claim 37 (depends on 27) The method of claim 27, wherein the protective agent comprises about 0.05 to about 0.4 grams of the at least one preservative agent per 0.2 ml of the protective agent. ### Claim 38 (depends on 30) The method of claim 30, wherein the EDTA is K3EDTA. ### Claim 39 (depends on 30) The method of claim 30, wherein the EDTA is present in an amount of about 20 g/l to about 150 g/l of the protective agent. ### Claim 40 (depends on 39) The method of claim 39, wherein the EDTA is present in an amount of about 50 g/l to about 100 g/l of the protective agent. ### Claim 41 (depends on 30) The method of claim 30, wherein the glycine is present in an amount of about 10 g/l to about 150 g/l of the protective agent. ### Claim 42 (depends on 41) The method of claim 41, wherein the glycine is present in an amount of about 35 g/l to about 100 g/l of the protective agent. ### Claim 43 (depends on 27) The method of claim 27, wherein the imidazolidinyl urea is present in an amount of about 300 g/l to about 700 g/l of the protective agent. ### Claim 44 (depends on 27) The method of claim 27, wherein the diazolidinyl urea is present in an amount of about 50 g/l to about 400 g/l of the protective agent. ### Claim 45 (depends on 27) The method of claim 27, wherein the composition comprises about 0.05 to about 1.0 ml of the protective agent. ### Claim 46 (depends on 27) The method of claim 27, wherein the composition comprises about 0.1 to about 0.3 ml of the protective agent. ### Claim 47 (depends on 27) The method of claim 27, wherein the composition comprises about 0.2 ml of the protective agent. ### Claim 48 (depends on 27) The method of claim 27, wherein the composition comprises about 10 ml of the whole blood.